{"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"groups":[{"description":"Vorinostat capsules given 200 mg b.i.d., 300 mg q.d., or 400 mg q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break).\n\nBortezomib injection. Treatment in 21 day cycles (participants received bortezomib 0.7 mg/m\\^2, 0.9 mg/m\\^2, 1.1 mg/m\\^2, or 1.3 mg/m\\^2 twice weekly on Days 1, 4, 8, and 11 or on Days 4, 8, 11, and 15 of each cycle, depending on dose level.","id":"BG000","title":"All Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.1","value":"60.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}